Patients enrolled in the two phase III studies were the worst cases (see inclusion criteria for the trials), and they got 150-200 units of Botox per patient. I don't know why he wrote 200 units or more. I think the drug is already being used off-label for migraine and since reimbursement is likely, use will probably grow.
Market Data 
Markets 
AI
